查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1872671

全球聚乙二醇化藥物市場：依分子、應用、分銷管道和地區劃分（2035-2035 年）

Global Pegylated Drugs Market Research Report Information by Molecule, by Application, by Distribution Channel, and by Region Forecast till 2035
出版日期: | 出版商: Market Research Future | 英文 175 Pages | 訂單完成後即時交付

價格

預計到 2035 年，全球聚乙二醇化藥物市場規模將達到 264.9752 億美元，預測期內複合年增長率 (CAGR) 為 5.17%。聚乙二醇化是將一個或多個聚乙二醇 (PEG) 分子連接到藥物上的過程，可以提高藥物的穩定性和溶解度，延長其在體內的停留時間，同時抑制免疫反應。這些優勢可以減少副作用，提高患者依從性，並促進蛋白質療法和單株抗體等先進生物製藥的更廣泛應用。

採用聚乙二醇化技術的生物製劑是市場的主要推動力

透過先進的聚乙二醇化技術不斷創新，改良生物製劑，是聚乙二醇化藥物市場的主要推動力。聚乙二醇化（PEGylation）是一種能夠增強生物分子治療效果並促進其吸收的工藝，其主要作用機制是降低免疫反應，因此這項技術對於開發先進生物製劑至關重要。這些特性是聚乙二醇化療法在慢性病和難治性疾病領域獲得大量研發投入和廣泛應用的主要原因。

區域分析

全球聚乙二醇化藥物市場正以相對穩定的速度成長。北美地區佔最大佔有率，這主要得益於其重要的藥物獲準和技術進步。歐洲市場持續成長，這得益於積極的研發投入和慢性病的高發生率。亞太地區則因其癌症病例的增加、人口老化以及監管支持，成為快速發展的地區。其他地區由於醫療保健系統的改善和生物製劑的廣泛應用，增長速度有所放緩。

策略市場阻礙因素

儘管市場受到強勁推動因素的支撐，但仍存在諸多挑戰，包括高昂的製造成本、複雜的監管流程以及藥物潛在的副作用。這些障礙會延緩產品開發進程，延長上市時間。解決這些問題對於跟上市場步伐至關重要。

報告主要內容

  • 2024年市場規模：151.8126億美元
  • 2035年市場規模：264.9752億美元
  • 複合年增長率（2025-2035年）：5.17%
  • 基準年：2024年
  • 市場預測期：2025-2035年

本報告分析了全球聚乙二醇化藥物市場，提供了市場定義和概述、影響市場成長的各種因素分析、市場規模趨勢和預測、依區隔市場、地區和主要國家/地區劃分的市場區隔、競爭格局以及主要公司的簡介。

目錄

第一章：摘要整理

第二章：市場概覽

第三章：研究方法

第四章：市場動態

  • 推動因素
    • 慢性病發生率上升
    • 生物學進展
    • 近期核准的聚乙二醇化藥物
  • 阻礙因素
    • 高額的生產成本
    • 監理壁壘
    • 潛在的副作用
  • 機遇
    • 新興市場
    • 創新藥物遞送系統
    • 個人化治療醫藥

第五章 市場因素分析

  • 波特五力模型
  • 新冠疫情對全球聚乙二醇化藥物市場的影響
  • 抗聚乙二醇抗體的定性分析及其對聚乙二醇化藥物的影響

第六章：全球聚乙二醇化藥物市場（依分子分類）

  • 概述
  • 大分子藥物
    • 蛋白質和勝肽
    • 酶
    • 適體
  • 小分子藥物
  • 脂質奈米顆粒 (LNP) 和脂質體

第七章：全球聚乙二醇化藥物市場（依分子分類）應用

  • 概述
  • 腫瘤學
  • 神經科學
  • 自體免疫疾病
  • 血液學
  • 其他

第八章 全球聚乙二醇化藥物市場（依通路劃分）

  • 概述
  • 醫院藥房
  • 線上藥房
  • 零售藥房

第九章 全球聚乙二醇化藥物市場（依地區劃分）

  • 概述
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國王國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他
  • 世界其他地區
    • 中東和非洲
    • 南美洲

第十章：競爭格局

  • 市佔率分析
  • 競爭概覽
  • 上市公司股票概覽
  • 主要公司財務趨勢比較分析
  • 主要發展動態及成長策略

第十一章：公司簡介

  • 安進公司
  • 輝瑞公司公司。
  • 百健
  • 拜耳股份公司
  • 武田製藥股份有限公司
  • 諾和諾德公司
  • 山道士集團股份公司
  • 阿斯特捷利康
  • 科赫魯斯生物科學有限公司
  • F.霍夫曼拉羅什有限公司
  • 強生公司
  • ALNYLAM 藥廠
  • 施維耶實驗室

第 12 章：資料引用

Product Code: MRFR/Pharma/6964-CR

The Global Pegylated Drugs Market is expected to hit USD 26,497.52 million by 2035, registering a CAGR of 5.17% during the forecast period. PEGylation is the process in which one or more PEG molecules are linked to drugs to make them more stable, more soluble, and their duration in the body is increased while immune reactions are lowered. These advantages result in fewer side effects, better patient compliance, and more extensive use of advanced biopharmaceuticals such as protein therapies and monoclonal antibodies.

PEGylation-Enabled Biologics as the Core Market Driver

Ongoing biologics innovations that have been improved by the advanced methods of PEGylation are the most overwhelming factor driving the PEGylated drugs market. PEGylation is the process that increases the therapeutic performance of biomolecules, can uptake more easily, mainly due to decreased immune reactions. Hence, this technique is a requisite for advanced biologic drug development. These features are the main reasons behind the huge R&D spending and the extended application of PEGylated therapies in chronic and hard-to-treat diseases.

Detailed Sub-Segment Summary

Molecule

  • Protein & Peptide: Improves therapeutic targeting and durability.

Enzyme: Provides essential support for metabolic repair.

Aptamer: Precision molecules enhancing targeted treatment delivery.

  • Small Molecular Drugs: Versatile agents with rapid therapeutic impact.
  • Lipid Nanoparticles: Cutting-edge systems for drug encapsulation.
  • Liposomes: Safe carriers offering effective drug release.

Application

  • Oncology: Advances cancer treatment through targeted options.
  • Neurology: Addresses complex disorders of the nervous system.
  • Autoimmune Diseases: Helps balance immune system overactivity.
  • Haematology: Enhances care for blood-related medical conditions.
  • Others: Encompasses various emerging treatment areas.

Distribution Channel

  • Hospital Pharmacy: Central hub for specialized clinical therapies.
  • Online Pharmacy: Expands accessibility to prescription medications.
  • Retail Pharmacy: Broad distribution for general pharmaceutical needs.

Regional Analysis

The global PEGylated drugs market is expanding at a relatively consistent pace. North America accounts for the largest share due to the major drug approvals and technological advancements, while Europe is growing through robust R&D and high prevalence of chronic diseases. Asia-Pacific stands out as the quickly developing region thanks to the rising cancer cases, aging populations, and regulatory support, whereas the Rest of the World is recording moderate growth because of improving healthcare systems and growing biologics adoption.

Strategic Market Restraints

The market is still debating high production costs, complicated regulatory processes, and possible side effects of the drugs, although it is driven by strong factors. The obstacles slow down product development and increase the commercialization period. The problems must be solved in order to keep up with the market pace.

Key Report Attributes

  • Market Size 2024: USD 15,181.26 Million
  • Market Size 2035: USD 26,497.52 Million
  • CAGR (2025-2035): 5.17%
  • Base Year: 2024
  • Market Forecast Period: 2025-2035

Market Segmentation Growth

  • By Molecule: Macromolecular Drugs - 5.94%, Small Molecular Drugs - 2.87%.
  • By Application: Oncology - 7.73%, Neurology - 4.72%.
  • By Distribution Channel: Hospital Pharmacy - 4.05%, Online Pharmacy - 7.16%.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 DATA MINING PROCESS
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 SECONDARY RESEARCH DATA FLOW:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 PRIMARY RESEARCH DATA FLOW:
    • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
    • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
  • 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
    • 3.6.1 REVENUE ANALYSIS APPROACH
  • 3.7 DATA FORECASTING
    • 3.7.1 DATA FORECASTING TYPE
  • 3.8 DATA MODELING
    • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
    • 3.8.2 DATA MODELING:
  • 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES
    • 4.2.2 ADVANCEMENTS IN BIOLOGICS
    • 4.2.3 RECENTLY APPROVED PEGYLATED DRUGS
  • 4.3 RESTRAINTS
    • 4.3.1 HIGH PRODUCTION COSTS
    • 4.3.2 REGULATORY HURDLES
    • 4.3.3 POTENTIAL SIDE EFFECTS
  • 4.4 OPPORTUNITY
    • 4.4.1 EMERGING MARKETS
    • 4.4.2 INNOVATIVE DRUG DELIVERY SYSTEMS
    • 4.4.3 PERSONALIZED MEDICINE

5 MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES MODEL
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 BARGAINING POWER OF SUPPLIERS
    • 5.1.3 THREAT OF SUBSTITUTES
    • 5.1.4 BARGAINING POWER OF BUYERS
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 IMPACT OF COVID-19 ON THE GLOBAL PEGYLATED DRUGS MARKET
  • 5.3 QUALITATIVE ANALYSIS ON ANTI-PEG ANTIBODIES AND IMPACT ON PEGYLATED DRUGS

6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE

  • 6.1 OVERVIEW
  • 6.2 MACROMOLECULAR DRUGS
    • 6.2.1 PROTEIN AND PEPTIDE
    • 6.2.2 ENZYME
    • 6.2.3 APTAMER
  • 6.3 SMALL MOLECULAR DRUGS
  • 6.4 LIPID NANOPARTICLES (LNP) AND LIPOSOMES

7 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION

  • 7.1 OVERVIEW
  • 7.2 ONCOLOGY
  • 7.3 NEUROLOGY
  • 7.4 AUTOIMMUNE DISEASES
  • 7.5 HAEMATOLOGY
  • 7.6 OTHERS

8 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CAHNNEL

  • 8.1 OVERVIEW
  • 8.2 HOSPITAL PHARMACY
  • 8.3 ONLINE PHARMACY
  • 8.4 RETAIL PHARMACY

9 GLOBAL PEGYLATED DRUGS MARKET, BY REGION

  • 9.1 OVERVIEW
  • 9.2 NORTH AMERICA
    • 9.2.1 US
    • 9.2.2 CANADA
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 FRANCE
    • 9.3.3 UK
    • 9.3.4 ITALY
    • 9.3.5 SPAIN
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA-PACIFIC
    • 9.4.1 CHINA
    • 9.4.2 INDIA
    • 9.4.3 JAPAN
    • 9.4.4 AUSTRALIA
    • 9.4.5 SOUTH KOREA
    • 9.4.6 REST OF ASIA-PACIFIC
  • 9.5 REST OF THE WORLD
    • 9.5.1 MIDDLE EAST & AFRICA
    • 9.5.2 SOUTH AMERICA
      • 9.5.2.1 BRAZIL
      • 9.5.2.2 MEXICO
      • 9.5.2.3 ARGENTINA
      • 9.5.2.4 REST OF SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 MARKET SHARE ANALYSIS, 2024
  • 10.3 COMPETITOR DASHBOARD
  • 10.4 PUBLIC PLAYERS STOCK SUMMARY
  • 10.5 CMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
  • 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 10.6.1 PRODUCT APPROVAL
    • 10.6.2 PRODUCT EXPANSION
    • 10.6.3 APPROVAL DENIED
    • 10.6.4 PRODUCT DISCONTINUATION
    • 10.6.5 AGREEMENT/ACQUISITION
    • 10.6.6 CLINICAL TRIAL FINDINGS

11 COMPANY PROFILES

  • 11.1 AMGEN INC.
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCTS OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 PFIZER INC.
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCTS OFFERED
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 KEY STRATEGIES
  • 11.3 BIOGEN
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCTS OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 KEY STRATEGIES
  • 11.4 BAYER AG
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 SWOT ANALYSIS
    • 11.4.6 KEY STRATEGY
  • 11.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCT OFFERED
    • 11.5.4 KEY DEVELOPMENTS
    • 11.5.5 KEY STRATEGIES
  • 11.6 NOVO NORDISK A/S
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 SWOT ANALYSIS
    • 11.6.6 KEY STRATEGIES
  • 11.7 SANDOZ GROUP AG
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 FINANCIAL OVERVIEW
    • 11.7.3 PRODUCTS OFFERED
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 KEY STRATEGIES
  • 11.8 ASTRAZENECA
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 FINANCIAL OVERVIEW
    • 11.8.3 PRODUCTS OFFERED
    • 11.8.4 KEY DEVELOPMENTS
    • 11.8.5 KEY STRATEGIES
  • 11.9 COHERUS BIOSCIENCES, INC.
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 FINANCIAL OVERVIEW
    • 11.9.3 PRODUCTS OFFERED
    • 11.9.4 KEY DEVELOPMENTS
    • 11.9.5 KEY STRATEGIES
  • 11.10 F. HOFFMANN-LA ROCHE LTD.
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 FINANCIAL OVERVIEW
    • 11.10.3 PRODUCTS OFFERED
    • 11.10.4 KEY DEVELOPMENTS
    • 11.10.5 SWOT ANALYSIS
    • 11.10.6 KEY STRATEGIES
  • 11.11 JOHNSON & JOHNSON INC.
    • 11.11.1 COMPANY OVERVIEW
    • 11.11.2 FINANCIAL OVERVIEW
    • 11.11.3 PRODUCTS OFFERED
    • 11.11.4 KEY DEVELOPMENTS
    • 11.11.5 SWOT ANALYSIS
    • 11.11.6 KEY STRATEGIES
  • 11.12 ALNYLAM PHARMACEUTICALS, INC.
    • 11.12.1 COMPANY OVERVIEW
    • 11.12.2 FINANCIAL OVERVIEW
    • 11.12.3 PRODUCTS OFFERED
    • 11.12.4 KEY DEVELOPMENTS
    • 11.12.5 KEY STRATEGIES
  • 11.13 LES LABORATOIRES SERVIER
    • 11.13.1 COMPANY OVERVIEW
    • 11.13.2 FINANCIAL OVERVIEW
    • 11.13.3 PRODUCT OFFERED
    • 11.13.4 KEY DEVELOPMENTS
    • 11.13.5 KEY STRATEGIES

12 DATA CITATIONS

LIST OF TABLES

  • TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
  • TABLE 2 RECENTLY APPROVED PEGYLATED DRUGS IN U.S., AUSTRALIA, JAPAN, AND CANADA
  • TABLE 3 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 4 GLOBAL PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 5 GLOBAL PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 6 GLOBAL PEGYLATED DRUGS MARKET, FOR PROTEIN AND PEPTIDE, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 7 GLOBAL PEGYLATED DRUGS MARKET, FOR ENZYME, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 8 GLOBAL PEGYLATED DRUGS MARKET, FOR APTAMER, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 9 GLOBAL PEGYLATED DRUGS MARKET, FOR SMALL MOLECULAR DRUGS, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 10 GLOBAL PEGYLATED DRUGS MARKET, FOR LIPID NANOPARTICLES (LNP) AND LIPOSOMES, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 11 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 12 GLOBAL PEGYLATED DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 13 GLOBAL PEGYLATED DRUGS MARKET, FOR NEUROLOGY, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 14 GLOBAL PEGYLATED DRUGS MARKET, FOR AUTOIMMUNE DISEASES, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 15 GLOBAL PEGYLATED DRUGS MARKET, FOR HAEMATOLOGY, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 16 GLOBAL PEGYLATED DRUGS MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 17 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 18 GLOBAL PEGYLATED DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 19 GLOBAL PEGYLATED DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 20 GLOBAL PEGYLATED DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 21 GLOBAL PEGYLATED DRUGS MARKET, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 22 NORTH AMERICA PEGYLATED DRUGS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 23 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 24 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 25 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 26 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 27 US: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 28 US: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 29 US: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 30 US: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 31 CANADA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 32 CANADA: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 33 CANADA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 34 CANADA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 35 EUROPE PEGYLATED DRUGS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 36 EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 37 EUROPE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 38 EUROPE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 39 EUROPE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 40 GERMANY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 41 GERMANY: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 42 GERMANY: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 43 GERMANY: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 44 FRANCE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 45 FRANCE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 46 FRANCE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 47 FRANCE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 48 UK: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 49 UK: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 50 UK: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 51 UK: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 52 ITALY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 53 ITALY: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 54 ITALY: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 55 ITALY: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 56 SPAIN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 57 SPAIN: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 58 SPAIN: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 59 SPAIN: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 60 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 61 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 62 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 63 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 64 ASIA-PACIFIC PEGYLATED DRUGS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 65 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 66 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 67 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 68 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 69 CHINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 70 CHINA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 71 CHINA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 72 CHINA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 73 INDIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 74 INDIA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 75 INDIA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 76 INDIA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 77 JAPAN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 78 JAPAN: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 79 JAPAN: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 80 JAPAN: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 81 AUSTRALIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 82 AUSTRALIA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 83 AUSTRALIA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 84 AUSTRALIA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 85 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 86 SOUTH KOREA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 87 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 88 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 89 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 90 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 91 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 92 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 93 REST OF THE WORLD PEGYLATED DRUGS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 94 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 95 REST OF THE WORLD: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 96 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 97 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 98 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 99 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 100 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 101 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 102 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  • TABLE 103 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 104 SOUTH AMERICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 105 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 106 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 107 BRAZIL: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 108 BRAZIL: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 109 BRAZIL: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 110 BRAZIL: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 111 MEXICO: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 112 MEXICO: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 113 MEXICO: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 114 MEXICO: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 115 ARGENTINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 116 ARGENTINA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 117 ARGENTINA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 118 ARGENTINA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 119 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
  • TABLE 120 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
  • TABLE 121 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 122 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 123 PRODUCT APPROVAL
  • TABLE 124 PRODUCT EXPANSION
  • TABLE 125 APPROVAL DENIED
  • TABLE 126 PRODUCT DISCONTINUATION
  • TABLE 127 AGREEMENT/ACQUISITION
  • TABLE 128 CLINICAL TRIAL FINDINGS
  • TABLE 129 AMGEN INC.: PRODUCTS OFFERED
  • TABLE 130 AMGEN INC.: KEY DEVELOPMENTS
  • TABLE 131 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 132 PFIZER INC.: KEY DEVELOPMENTS
  • TABLE 133 BIOGEN: PRODUCTS OFFERED
  • TABLE 134 BIOGEN: KEY DEVELOPMENTS
  • TABLE 135 BAYER AG: PRODUCTS OFFERED
  • TABLE 136 BAYER AG: KEY DEVELOPMENTS
  • TABLE 137 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED
  • TABLE 138 TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY DEVELOPMENTS
  • TABLE 139 NOVO NORDISK A/S: PRODUCTS OFFERED
  • TABLE 140 NOVO NORDISK A/S: KEY DEVELOPMENTS
  • TABLE 141 SANDOZ GROUP AG: PRODUCTS OFFERED
  • TABLE 142 SANDOZ GROUP AG: KEY DEVELOPMENTS
  • TABLE 143 ASTRAZENECA: PRODUCTS OFFERED
  • TABLE 144 ASTRAZENECA: KEY DEVELOPMENTS
  • TABLE 145 COHERUS BIOSCIENCES, INC.: PRODUCTS OFFERED
  • TABLE 146 COHERUS BIOSCIENCES, INC.: KEY DEVELOPMENTS
  • TABLE 147 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 148 JOHNSON & JOHNSON INC.: PRODUCTS OFFERED
  • TABLE 149 ALNYLAM PHARMACEUTICALS, INC: PRODUCTS OFFERED
  • TABLE 150 ALNYLAM PHARMACEUTICALS, INC: KEY DEVELOPMENTS
  • TABLE 151 LES LABORATOIRES SERVIER: PRODUCTS OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL PEGYLATED DRUGS MARKET: STRUCTURE
  • FIGURE 2 GLOBAL PEGYLATED DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035)
  • FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2035)
  • FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2035)
  • FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PEGYLATED DRUGS MARKET
  • FIGURE 6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2024 & 2035 (USD MILLION)
  • FIGURE 7 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY MOLECULE, 2024
  • FIGURE 8 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION)
  • FIGURE 9 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY APPLICATION, 2024
  • FIGURE 10 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD MILLION)
  • FIGURE 11 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024
  • FIGURE 12 GLOBAL PEGYLATED DRUGS MARKET SHARE, BY REGION, 2024 & 2035 (USD MILLION)
  • FIGURE 13 GLOBAL PEGYLATED DRUGS MARKET SHARE, BY REGION, 2024 (%)
  • FIGURE 14 NORTH AMERICA PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
  • FIGURE 15 NORTH AMERICA PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
  • FIGURE 16 EUROPE PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
  • FIGURE 17 EUROPE PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
  • FIGURE 18 ASIA-PACIFIC PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
  • FIGURE 19 ASIA-PACIFIC PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
  • FIGURE 20 REST OF THE WORLD PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
  • FIGURE 21 REST OF THE WORLD PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
  • FIGURE 22 GLOBAL PEGYLATED DRUGS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
  • FIGURE 23 COMPETITOR DASHBOARD: GLOBAL PEGYLATED DRUGS MARKET
  • FIGURE 24 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 25 AMGEN INC.: SWOT ANALYSIS
  • FIGURE 26 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 27 PFIZER INC.: SWOT ANALYSIS
  • FIGURE 28 BIOGEN: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 29 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 30 BAYER AG: SWOT ANALYSIS
  • FIGURE 31 TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 32 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 33 NOVO NORDISK A/S: SWOT ANALYSIS
  • FIGURE 34 SANDOZ GROUP AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 35 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 36 COHERUS BIOSCIENCES, INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
  • FIGURE 39 JOHNSON & JOHNSON INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 40 JOHNSON & JOHNSON INC.: SWOT ANALYSIS
  • FIGURE 41 ALNYLAM PHARMACEUTICALS, INC: FINANCIAL OVERVIEW SNAPSHOT